The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
(2016) · Lung Transplantation · doi:10.3109/9781439802571-25 · Cited by 2,157
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Di Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Self-citationp53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes
Caelles, C., Helmberg, A., & Karin, M. (1994) · Nature · doi:10.1038/370220a0 · Cited by 843
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
Self-citationBinding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
Recruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Linke, S. P., Clarkin, K. C., Di Leonardo, A., Tsou, A., & Wahl, G. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.934 · Cited by 538
Self-citationHuang, L. C., Clarkin, K. C., & Wahl, G. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4827 · Cited by 384
Self-citationThe ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes.
Marechal, V, Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318
Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans
Fairbanks, L. D., Bofill, M., Ruckemann, K., & Simmonds, H. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29682 · Cited by 310
DNA-dependent protein kinase acts upstream of p53 in response to DNA damage
Woo, R. A., McLure, K. G., Lees-Miller, S. P., Rancourt, D. E., & Lee, P. W. K. (1998) · Nature · doi:10.1038/29343 · Cited by 309
Mladenovic, V., Domljan, Z., Rozman, B., Jajic, I., Mihajlovic, D., Dordevic, J., Popovic, M., Dimitrijevic, M., Zivkovic, M., Campion, G., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381111 · Cited by 303
Self-citationWeinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Self-citationRückemann, K., Fairbanks, L. D., Carrey, E. A., Hawrylowicz, C. M., Richards, D. F., Kirschbaum, B., & Simmonds, H. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21682 · Cited by 270
Self-citationThe basis of autoimmunity: Part I mechanisms of aberrant self-recognition
Theofilopoulos, A. N. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80095-6 · Cited by 240
Activation-induced apoptosis in lymphocytes
Green, D. R., & Scott, D. W. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90130-9 · Cited by 229
Cherwinski, H. M., Cohn, R. G., Cheung, P., Webster, D. J., Xu, Y. Z., Caulfield, J. P., Young, J. M., Nakano, G., & Ransom, J. T. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12093-4 · Cited by 222
Xu, X., Williams, J. W., Bremer, E. G., Finnegan, A., & Chong, A. S.-F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12398 · Cited by 216
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
Greene, S., Watanabe, K., Braatz-Trulson, J., & Lou, L. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00255-x · Cited by 197
Brazelton, T. R., & Randall E, M. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80090-2 · Cited by 195
Williamson, R. A., Yea, C. M., Robson, P. A., Curnock, A. P., Gadher, S., Hambleton, A. B., Woodward, K., Bruneau, J.-M., Hambleton, P., Moss, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22467 · Cited by 192
REGULATION OF B CELL FUNCTION BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1
Siemasko, K. F., Chong, A. S. F., Williams, J. W., Bremer, E. G., & Finnegan, A. (1996) · Transplantation · doi:10.1097/00007890-199602270-00020 · Cited by 183
Elder, R. T., Xu, X., Williams, J. W., Gong, H., Finnegan, A., & Chong, A. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.22 · Cited by 174
p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation.
Linke, S. P., Clarkin, K., & Wahl, G. M. (1997) · PubMed · Cited by 143
Self-citationSalmi, M., Rajala, P., & Jalkanen, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119389 · Cited by 137
Bartlett, R. R., & Schleyerbach, R. (1985) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(85)90003-7 · Cited by 131
Maintaining genetic stability through TP53 mediated checkpoint control.
Wahl, G. M., Sp, L., Tg, P., & Huang, L. (1997) · PubMed · Cited by 115
Self-citationKnecht, W., Bergjohann, U., Gonski, S., Kirschbaum, B. J., & Löffler, M. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0292h.x · Cited by 107
Self-citationp53 Is Covalently Linked to 5.8S rRNA
Fontoura, B. M. A., Sorokina, E. A., David, E., & Carroll, R. B. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5145 · Cited by 101
Knecht, W., & Löffler, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00145-2 · Cited by 101
Kremer, J. M. (1999) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(99)80034-1 · Cited by 93
Kuo, E., Hambleton, P. T., Kay, D. P., Evans, P. L., Matharu, S. S., Little, E., McDowall, N., Jones, C. B., Hedgecock, C. J. R., Yea, C., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9604437 · Cited by 91
Xu, X., Blinder, L., Shen, J., Gong, H., Finnegan, A., Williams, J. W., & Chong, A. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.167 · Cited by 87
Peters, G. J., Schwartsmann, G., Nadal, J. C., Laurensse, E. J., van Groeningen, C. J., van der Vijgh, W. J. F., & Pinedo, H. M. (1990) · PubMed · Cited by 80
Bader, B., Knecht, W., Fries, M., & Löffler, M. (1998) · Protein Expression and Purification · doi:10.1006/prep.1998.0925 · Cited by 55
Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice
Popović, S., & Bartlett, R. R. (1986) · Inflammation Research · doi:10.1007/bf01971235 · Cited by 54
Wu, M., Bellas, R. E., Shen, J., & Sonenshein, G. E. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1671 · Cited by 53
Cao, W., Kao, P. N., Aoki, Y., Xu, J. C., Shorthouse, R., & Morris, R. E. (1996) · PubMed · Cited by 51
Self-citationJöckel, J., Wendt, B., & Löffler, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00131-2 · Cited by 46
Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide
Giant, T. T., Mikecz, K., Bartlett, R. R., et al. (1992) · Immunopharmacology · doi:10.1016/0162-3109(92)90034-a · Cited by 44
Popović, S., & Bartlett, R. R. (1987) · Inflammation Research · doi:10.1007/bf01966492 · Cited by 43
Leflunomide prevents the development of experimentally induced myasthenia gravis
Vidic-Dankovic, B., Kosec, D. J., Damjanović, M., et al. (1995) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(95)00009-q · Cited by 41
Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.
Williamson, R. A., Yea, C., Robson, P. A., et al. (1996) · PubMed · Cited by 41
Purine nucleotide metabolism in phytohemagglutinin-induced human T lymphocytes
Barankiewicz, J., & Cohen, A. M. (1987) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(87)90333-x · Cited by 36
Hancock, W. W., Miyatake, T., Koyamada, N., KUT, J. P., Soares, M. P., Russell, M. E., Bach, F. H., & Sayegh, M. H. (1997) · Transplantation · doi:10.1097/00007890-199709150-00006 · Cited by 36
In vitro and in vivo effects of leflunomide, Brequinar, and cyclosporine on pyrimidine biosynthesis
Junior, H. T. S., Shorthouse, R., Löffler, M., et al. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(96)00523-4 · Cited by 33
Bartlett, R. R., Brendel, S., Zielinski, T., et al. (1996) · PubMed · Cited by 31
Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors
Danska, J. S., & Guidos, C. J. (1997) · Seminars in Immunology · doi:10.1006/smim.1997.0072 · Cited by 29
Junior, H. T. S., Cao, W., Shorthouse, R., & Morris, R. E. (1996) · PubMed · Cited by 28
Self-citationChatterjee, S., & Berger, N. A. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928444 · Cited by 27
Dimitrijevic, M., & Bartlett, R. R. (1996) · PubMed · Cited by 26
Lymphocyte-specific genomic instability and risk of lymphoid malignancy
Kirsch, I. R., & Lista, F. (1997) · Seminars in Immunology · doi:10.1006/smim.1997.0071 · Cited by 25
Cited by
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
GLIA: A novel drug discovery target for clinical pain
Watkins, L. R., & Maier, S. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1251 · Cited by 672
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-9-200211050-00007 · Cited by 353
Self-citationDrugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Metadata
- Authors
- Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 93
- Issue
- 3
- Pages
- 198-208
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W2054218135
- Cited by
- 420
- References
- 58
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.